CymaBay Therapeutics (CBAY) Received Roth Capital’s Coverage; Senator Investment Group LP Cut Delphi Automotive Plc (DLPH) Position

Senator Investment Group Lp decreased Delphi Automotive Plc (DLPH) stake by 37.5% reported in 2017Q3 SEC filing. Senator Investment Group Lp sold 1.13 million shares as Delphi Automotive Plc (DLPH)’s stock rose 13.84%. The Senator Investment Group Lp holds 1.88 million shares with $184.50 million value, down from 3.00M last quarter. Delphi Automotive Plc now has $4.97B valuation. The stock increased 0.99% or $0.55 during the last trading session, reaching $56.03. About 1.01 million shares traded. Delphi Technologies PLC (NYSE:DLPH) has risen 30.43% since January 28, 2017 and is uptrending. It has outperformed by 13.73% the S&P500.

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc has $18 highest and $2.25 lowest target. $15.40’s average target is 32.30% above currents $11.64 stock price. Cymabay Therapeutics Inc had 18 analyst reports since July 21, 2015 according to SRatingsIntel. As per Monday, July 17, the company rating was maintained by Piper Jaffray. On Wednesday, June 1 the stock rating was downgraded by H.C. Wainwright to “Neutral”. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Monday, September 11 by Piper Jaffray. Cantor Fitzgerald initiated the shares of CBAY in report on Tuesday, September 19 with “Buy” rating. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Monday, July 17 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, March 30 by H.C. Wainwright. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by H.C. Wainwright on Monday, January 30. On Wednesday, October 25 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Neutral” rating given on Wednesday, January 4 by H.C. Wainwright. The company was initiated on Tuesday, September 8 by H.C. Wainwright.

Investors sentiment increased to 1.32 in Q3 2017. Its up 0.22, from 1.1 in 2017Q2. It improved, as 30 investors sold DLPH shares while 173 reduced holdings. 83 funds opened positions while 185 raised stakes. 236.59 million shares or 5.31% less from 249.87 million shares in 2017Q2 were reported. Ameriprise Finance, Minnesota-based fund reported 820,705 shares. Marco Investment has invested 0.36% in Delphi Technologies PLC (NYSE:DLPH). Btc Capital has invested 0.05% of its portfolio in Delphi Technologies PLC (NYSE:DLPH). Pinebridge Invests Lp stated it has 0.01% of its portfolio in Delphi Technologies PLC (NYSE:DLPH). Carroll Fin Assocs Incorporated accumulated 25 shares or 0% of the stock. City Company reported 44 shares. Aperio Group Limited Liability Company has 0.06% invested in Delphi Technologies PLC (NYSE:DLPH) for 101,767 shares. Calamos Limited Company reported 79,041 shares. 3.53M were accumulated by Goldman Sachs Grp Inc Inc. Balyasny Asset Management Ltd Limited Liability Company reported 59,638 shares. Community National Bank Na owns 20 shares for 0% of their portfolio. Moreover, Fred Alger has 0.44% invested in Delphi Technologies PLC (NYSE:DLPH) for 945,149 shares. Parametric Portfolio Assocs Limited Liability reported 603,803 shares or 0.07% of all its holdings. Td Asset Mgmt accumulated 0.03% or 169,748 shares. Credit Suisse Ag holds 404,835 shares or 0.04% of its portfolio.

Since August 10, 2017, it had 1 buy, and 3 insider sales for $1.82 million activity. 8,500 Delphi Technologies PLC (NYSE:DLPH) shares with value of $836,682 were sold by COWGER GARY L. The insider De Vos Glen W. sold 2,100 shares worth $191,834. DELLAQUILA FRANK J bought $83,880 worth of stock or 1,000 shares. 8,475 Delphi Technologies PLC (NYSE:DLPH) shares with value of $874,544 were sold by Sidlik Thomas W.

Among 26 analysts covering Delphi Automotive LLP (NYSE:DLPH), 20 have Buy rating, 0 Sell and 6 Hold. Therefore 77% are positive. Delphi Automotive LLP had 83 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Buy” rating by Piper Jaffray on Monday, July 10. As per Thursday, October 26, the company rating was maintained by Cowen & Co. Buckingham Research upgraded Delphi Technologies PLC (NYSE:DLPH) on Monday, August 31 to “Buy” rating. The stock of Delphi Technologies PLC (NYSE:DLPH) has “Buy” rating given on Friday, February 3 by UBS. As per Friday, November 3, the company rating was maintained by Robert W. Baird. The stock of Delphi Technologies PLC (NYSE:DLPH) earned “Buy” rating by UBS on Tuesday, March 15. As per Thursday, October 12, the company rating was downgraded by Deutsche Bank. As per Thursday, January 12, the company rating was maintained by Barclays Capital. The stock of Delphi Technologies PLC (NYSE:DLPH) has “Buy” rating given on Friday, July 7 by RBC Capital Markets. The firm earned “Buy” rating on Thursday, September 14 by KeyBanc Capital Markets.

Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $510.58 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The company??s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.